|Disruption of the cereblon gene enhances hepatic AMPK activity and prevents high-fat diet-induced obesity and insulin resistance in mice.|
|Jump to Full Text|
|PMID: 23349485 Owner: NLM Status: MEDLINE|
|A nonsense mutation in cereblon (CRBN) causes a mild type of mental retardation in humans. An earlier study showed that CRBN negatively regulates the functional activity of AMP-activated protein kinase (AMPK) in vitro by binding directly to the α1-subunit of the AMPK complex. However, the in vivo role of CRBN was not studied. For elucidation of the physiological functions of Crbn, a mouse strain was generated in which the Crbn gene was deleted throughout the whole body. In Crbn-deficient mice fed a normal diet, AMPK in the liver showed hyperphosphorylation, which indicated the constitutive activation of AMPK. Since Crbn-deficient mice showed significantly less weight gain when fed a high-fat diet and their insulin sensitivity was considerably improved, the functions of Crbn in the liver were primarily investigated. These results provide the first in vivo evidence that Crbn is a negative modulator of AMPK, which suggests that Crbn may be a potential target for metabolic disorders of the liver.|
|Kwang Min Lee; Seung-Joo Yang; Yong Deuk Kim; Yoo Duk Choi; Jong Hee Nam; Cheol Soo Choi; Hueng-Sik Choi; Chul-Seung Park|
Related Documents :
|24569415 - Dietary fish oil improves endothelial function and lowers blood pressure via suppressio...
1765085 - Mechanisms of dramatic fluctuations of ornithine decarboxylase activity upon tonicity c...
23758335 - Effects of inclusion of graded amounts of soya bean hulls on feed intake, chewing activ...
21779555 - (-)-epigallocatechin-3-gallate increases the expression of genes related to fat oxidati...
22045025 - Consumption of high ω-3 fatty acid diet suppressed prostate tumorigenesis in c3(1) tag...
6187205 - Effect of short-term dietary fat on cell growth in rat gastrointestinal mucosa and panc...
|Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2013-01-24|
|Title: Diabetes Volume: 62 ISSN: 1939-327X ISO Abbreviation: Diabetes Publication Date: 2013 Jun|
|Created Date: 2013-05-24 Completed Date: 2013-08-02 Revised Date: 2014-06-03|
Medline Journal Info:
|Nlm Unique ID: 0372763 Medline TA: Diabetes Country: United States|
|Languages: eng Pagination: 1855-64 Citation Subset: AIM; IM|
|APA/MLA Format Download EndNote Download BibTex|
AMP-Activated Protein Kinases
Diet, High-Fat / adverse effects*
Insulin Resistance / genetics, physiology
Liver / enzymology*
Obesity / etiology, genetics, therapy
Peptide Hydrolases / genetics, metabolism*
|EC 22.214.171.124/AMP-Activated Protein Kinases; EC 3.4.-/CRBN protein, human; EC 3.4.-/Peptide Hydrolases|
Journal ID (nlm-ta): Diabetes
Journal ID (iso-abbrev): Diabetes
Journal ID (hwp): diabetes
Journal ID (pmc): diabetes
Journal ID (publisher-id): Diabetes
Publisher: American Diabetes Association
© 2013 by the American Diabetes Association.
Received Day: 02 Month: 8 Year: 2012
Accepted Day: 07 Month: 1 Year: 2013
Print publication date: Month: 6 Year: 2013
Electronic publication date: Day: 17 Month: 5 Year: 2013
Volume: 62 Issue: 6
First Page: 1855 Last Page: 1864
PubMed Id: 23349485
Publisher Id: 1030
|Disruption of the Cereblon Gene Enhances Hepatic AMPK Activity and Prevents High-Fat Diet–Induced Obesity and Insulin Resistance in Mice|
|Kwang Min Lee1|
|Yong Deuk Kim2|
|Yoo Duk Choi3|
|Jong Hee Nam3|
|Cheol Soo Choi45|
1School of Life Sciences and Cell Dynamics Research Center and National Leading Research Laboratory for Ion Channels, Gwangju Institute of Science and Technology, Gwangju, Republic of Korea
2National Creative Research Initiatives Center for Nuclear Receptor Signals, Hormone Research Center, School of Biological Sciences and Technology, Chonnam National University, Gwangju, Republic of Korea
3Department of Pathology, Chonnam National University Medical School, Gwangju, Republic of Korea
4Korea Mouse Metabolic Phenotyping Center, Lee Gil Ya Cancer and Diabetes Institute, Incheon, Republic of Korea
5Division of Endocrinology, Gil Medical Center, Gachon University, Incheon, Republic of Korea
|Correspondence: Corresponding author: Chul-Seung Park, firstname.lastname@example.org.
Initially, cereblon (CRBN) was identified as a target gene for a mild type of mental retardation in humans (1) and was subsequently characterized in several different functional contexts. CRBN interacts directly with large-conductance calcium-activated potassium channels and regulates their surface expression (2). Later, CRBN was identified as a primary target for thalidomide-induced teratogenicity and as a substrate receptor for the E3 ligase complex (3). More recently, we reported that CRBN interacts directly with the α1-subunit of AMP-activated protein kinase (AMPK) and inhibits activation of the enzyme in vitro (4).
AMPK is a metabolic master switch in response to variations in cellular energy homeostasis (5). The activity of AMPK can be modulated by the phosphorylation of a threonine at position 172 (Thr172) in the α-subunit by upstream kinases such as LKB1 (6). AMPK inactivates acetyl-CoA carboxylase (ACC) via direct protein phosphorylation and suppresses expression of lipogenic genes, including fatty acid synthase (FAS), thereby inhibiting fatty acid synthesis (7,8). AMPK is implicated in the regulation of hepatic glucose and lipid metabolism, thereby affecting the energy status of the whole body (7,9). Moreover, AMPK was identified as a major pharmacological target protein for the treatment of metabolic diseases. For example, experimental animal models of type 2 diabetes and obesity show that activation of AMPK by metformin or 5-aminoimidazole-4-carboxamide ribonucleoside reduces blood glucose levels and improves lipid metabolism (10–12).
Our recent study found that CRBN interacted directly with the AMPK α1-subunit both in cultured cell lines and in vitro, and the binding sites within the two proteins were localized (4). The levels of the AMPK γ-subunit and CRBN in the AMPK complex varied in a reciprocal manner; i.e., a higher CRBN content corresponded to lower γ-subunit content. AMPK activation was reduced as its γ-subunit content was decreased by CRBN. Thus, it was proposed that CRBN may act as a negative regulator of AMPK in vivo (4). The aims of the current study were to test this hypothesis and to understand the physiological role(s) of CRBN by generating Crbn knockout (KO) mice. The results showed that AMPK activity was activated constitutively in Crbn KO mice under normal conditions and that Crbn KO mice fed a long-term high-fat diet (HFD) showed a marked improvement in their metabolic status.
For generation of Crbn KO mice, heterozygous F1 animals were provided by the knockout mouse service (Macrogen, Seoul, Korea). The targeting vector used to delete a segment containing exon 1 of the Crbn gene (1.1 kb) was constructed using a 5′ short arm fragment (2.6 kb) and a 3′ long arm fragment (7.3 kb), which were ligated into the pOsdupdel vector. The targeting vector was constructed by replacing the 1.1-kb genomic segment with the neomycin cassette. Heterozygous F1 animals were backcrossed with C57BL/6N mice over at least 10 generations before this study. Heterozygous males and females were then bred to produce Crbn KO mice. The genotypes of the WT and Crbn KO mice were determined by RT-PCR using tail genomic DNA and primers specific for wild-type (WT) or Crbn KO alleles (P1, P2, and P3 in Fig. 1A).
Mice were maintained on a standard chow diet and water ad libitum in pathogen-free conditions and housed in a room with a 12-h light-dark cycle. For induction of obesity and insulin-resistant phenotypes, male mice (5 weeks old; n = 12–13 per group) were fed an HFD (Research Diet D12492) for 14 weeks while being housed separately. Body weight and food intake were recorded throughout the experiments. Food intake was assessed by determining the difference in food weight during a 7-day period. All experiments were approved by the Gwangju Institute of Science and Technology Animal Care and Use Committee.
Glucose tolerance tests were performed by intraperitoneally injecting mice with D-glucose (Sigma) at a dose of 2 g/kg body wt after a 16-h fast. Insulin tolerance tests were performed intraperitoneally by injecting human insulin (Sigma) at a dose of 0.75 units/kg body wt after a 4-h fast. Blood samples were collected via the tail vein, and plasma glucose levels were measured using a glucometer (Roche Diagnostics).
At the end of the 14-week period, mice were killed and the livers fixed in 10% formalin and embedded in paraffin. Paraffin sections (5 μm) were then subjected to hematoxylin and eosin (H&E) staining. Cryosections were stained using Oil Red O and counterstained with hematoxylin to visualize the lipid droplets.
Total RNA was isolated from liver tissues of the indicated mice with TRIzol reagent (Invitrogen) according to the manufacturer’s protocol. Expression was normalized against the levels of β-actin mRNA. The sequences of the primers used in the PCR analyses are described in Supplementary Table 1.
All values were expressed as means ± SEM. Significant differences between groups were determined using two-tailed unpaired Student t tests, and multiple comparisons were performed using one-way ANOVA or two-way repeated-measures ANOVA. Differences with P < 0.05 were considered statistically significant and are shown in the Figure legends.
Crbn KO mice were generated to elucidate the in vivo function of Crbn. (Fig. 1A). PCR analysis of genomic DNA from the tails of Crbn KO mice confirmed the loss of the WT gene and the presence of the targeting vector (Fig. 1B). Crbn protein was not detected in the liver, skeletal muscle (SKM), or white adipose tissue (WAT) (Fig. 1C), and all other tissues were tested by Western blot analysis. The daily body weight of both male and female KO mice fed a normal diet from weaning to 12 weeks of age was comparable with that of WT mice (Supplementary Fig. 1A).
Our previous study showed that CRBN inhibits the activation of AMPK in vitro by interacting directly with the α1-subunit of AMPK (AMPK-α1) (4); therefore, the current study examined whether Crbn deficiency affected AMPK activation (Fig. 1D). First, the phosphorylation of AMPK Thr172 was measured in primary mouse embryonic fibroblasts (MEFs). The amount of phosphorylated (P-)AMPK-α increased in Crbn+/− and Crbn−/− MEFs (Fig. 1E). ACC is inactivated by phosphorylation of serine 79 after AMPK activation; therefore, we next measured the levels of P-ACC. Increases in P-AMPK were accompanied by higher levels of P-ACC in Crbn+/− and Crbn−/− MEFs compared with Crbn+/+ MEFs (Fig. 1F). It was shown previously that the binding of exogenous CRBN to AMPK decreases the amount of γ-subunits in the AMPK complex (4); therefore, the effects of Crbn KO on the AMPK complex were tested by immunoprecipitating the endogenous AMPK complex from MEFs (Supplementary Fig. 1C–F). The intensity of the AMPK β-band did not change greatly (Supplementary Fig. 1D); however, the intensity of the γ1-subunit band was significantly higher in both Crbn+/− and Crbn−/− MEFs compared with Crbn+/+ (Supplementary Fig. 1E). These results support the hypothesis that CRBN suppresses AMPK activation by reducing the affinity of the γ1-subunit for the AMPK complex (4).
For testing of whether Crbn deficiency affected the function of AMPK in vivo, the enzymatic activity of AMPK was assessed in the mouse liver by determining its phosphorylation state. AMPK phosphorylation was 8.2-fold higher in Crbn KO mice than in WT (Fig. 2A and Supplementary Fig. 2A). Subsequently, the effects of Crbn KO were investigated under conditions known to activate endogenous AMPK (13,14). The level of AMPK phosphorylation increased in a time-dependent manner in both WT and Crbn KO mice after injection of metformin; however, the level of P–AMPK-α was higher in Crbn KO mice than that in WT (Fig. 2B and Supplementary Fig. 2B). Similar results were obtained with primary MEFs cultured under serum-deprived conditions. (Supplementary Fig. 2C and D). Overall, these results suggest that AMPK is hyperactivated in the absence of Crbn in vivo, which further indicates that Crbn acts as an endogenous negative regulator of AMPK.
For elucidation of the physiological role(s) of Crbn in vivo, both WT and Crbn KO mice were fed either a normal chow diet or an HFD (Fig. 3A and B). The HFD-induced weight increase was slower and the level of weight gain was much less for Crbn KO mice than for the WT. The body weight of WT mice fed the HFD was significantly higher than that of mice fed the chow diet at 2 weeks, whereas the Crbn KO mice were significantly heavier at 7 weeks (Fig. 3E). The difference in the HFD-induced weight gain of WT and Crbn KO mice was not attributable to their food consumption (Fig. 3F). The initial average weight of Crbn KO mice was also not significantly different from that of WT mice (Fig. 3E and Supplementary Table 2).
Necropsies were performed on both WT and Crbn KO mice, which showed that Crbn KO mice fed the HFD had a lower epididymal fat mass than WT (Fig. 3C and D). After 14 weeks on the HFD, the average epididymal fat mass of WT mice was 2.7-fold higher than that of Crbn KO. Crbn KO mice fed with a normal chow diet had lower epididymal fat masses than WT (Fig. 3G). These observations suggest that mice lacking Crbn experienced greater protection from body fat accumulation and obesity caused by high fat intake.
The effects of HFD on the morphology and lipid content of the liver in Crbn KO mice were tested next. A comparison of the livers from HFD-fed WT and Crbn KO mice showed that WT livers were much larger, heavier, and paler than those of Crbn KO mice (Fig. 3D and Fig. 4A). The hepatic triglyceride (TG) content was significantly lower in HFD-fed Crbn KO mice than in the WT. The TG content was also lower in Crbn KO mice fed the normal chow diet than in WT (Fig. 4B). Hepatic cholesterol levels were also higher in both WT and Crbn KO mice fed an HFD (Fig. 4C).
In agreement with these results, H&E staining of liver sections showed that the livers of HFD-fed WT mice contained unstained lipid inclusions, which were less abundant in the livers of HFD-fed Crbn KO mice (Figs. 4D–G). Oil Red O staining of lipids further confirmed the massive accumulation of neutral lipids in the livers of WT mice fed an HFD, which is a hallmark of fatty liver, but not in the livers of Crbn KO fed an HFD (Figs. 4H–K). Thus, Crbn deficiency prevented the accumulation of fats in the epididymal tissues and liver, which made the livers more resistant to fatty liver, which is normally caused by high fat intake.
Crbn KO mice were largely protected from HFD-induced obesity and fatty liver; therefore, we next investigated their metabolic parameters. When fed an HFD, WT mice showed significantly higher levels of serum glucose, insulin, and leptin than mice fed normal chow (Fig. 5A–C), which suggests impaired insulin sensitivity. However, the serum levels of glucose, insulin, and leptin were significantly lower in HFD-fed Crbn KO mice. Other plasma metabolic parameters were also measured in both WT and Crbn KO mice fed normal chow or the HFD (Supplementary Fig. 3). Under both diet conditions, WT and Crbn KO mice showed similar serum levels of TG, cholesterol, resistin, adiponectin, tumor necrosis factor-α, MCP-1, and plasminogen activator inhibitor-1. By contrast, the serum nonesterified FFA levels of Crbn KO mice fed an HFD were lower than those in the WT (Supplementary Fig. 3C), which agrees with a previous report showing that type 2 diabetic patients with a fatty liver are substantially more insulin resistant and have higher levels of plasma FFA (15). Increased glucose tolerance and insulin sensitivity were also confirmed in HFD-fed Crbn KO mice. (Fig. 5D and E). These results demonstrate that Crbn deficiency may prevent glucose intolerance and insulin resistance, which are normally induced by a long-term HFD.
For elucidation of the molecular basis of the phenotypic changes observed in Crbn KO mice fed an HFD, expression profiling was performed for several metabolic enzymes. AMPK activation was also monitored. The level of P-AMPK was lower in mice fed an HFD (Fig. 6A), which is in agreement with previous studies (16,17). The total AMPK expression level was not different between WT and Crbn KO mice fed a normal chow diet or an HFD, whereas P-AMPK was significantly higher in Crbn KO mice fed an HFD than in WT mice fed an HFD (Fig. 6B). Furthermore, the ratio of P-ACC to total ACC was consistent with the level of AMPK-α activation (Fig. 6D). Despite the hyperphosphorylation of AMPK, the expression levels of the AMPK upstream kinases, liver kinase and Ca2+/calmodulin-dependent protein kinase kinase β, were similar in Crbn KO mice and WT mice (Supplementary Fig. 4), suggesting that these kinases may not be involved in AMPK activation in Crbn KO mice.
There were no statistical differences in the expression of SREBP1C or ChREBP (Fig. 7A and B), a major regulator of lipogenesis (18,19) between the groups; however, the expression of PPARγ, a lipogenic transcription factor (20,21), was significantly lower in Crbn KO fed either a normal chow diet or an HFD compared with that in WT mice fed these diets (Fig. 7C). The expression of FAS, which is involved in fatty acid synthesis, and DGAT2, a rate-limiting enzyme that catalyzes the final step of TG synthesis (22,23), was reduced in Crbn KO mice fed a normal chow diet or the HFD (Fig. 7D and E). These results are consistent with the finding that the level of hepatic TG was lower in Crbn KO mice fed both the normal chow diet and the HFD compared with that in the WT mice (Fig. 4B). The expression levels of ACC1 and SCD1 mRNA were significantly lower in HFD-fed Crbn KO mice than in HFD-fed WT (Fig. 7F and G). Expression of G6Pase, but not PEPCK, was significantly lower in Crbn KO mice fed both the normal chow diet and the HFD than in WT (Fig. 7H and I). The expression of L-PK, which is a key enzyme involved in glycolysis, was significantly higher in WT mice fed the HFD; however, its upregulation was completely abrogated in Crbn KO mice fed the HFD (Fig. 7L). This result is consistent with serum glucose levels (Fig. 5A) because L-PK gene transcription is positively regulated by glucose and insulin (24,25). The pattern of AMPK activation (Fig. 6A) is also consistent with the reciprocal pattern of mRNA expression for L-PK and G6Pase (Fig. 7M and I); AMPK activation inhibits the expression of L-PK (25,26) and G6Pase (27). Expression of FGF21 was 10.3-fold higher in WT mice fed an HFD than in WT fed a normal chow diet (Fig. 7J), which is consistent with a previous report showing that obesity may be considered an FGF21-resistant state (28). However, FGF21 expression was only 3.7-fold higher in Crbn KO mice fed an HFD than that in Crbn KO mice fed normal chow. The mRNA expression levels of HMGCS, which is involved in cholesterol biosynthesis, were 1.8-fold higher in HFD-fed WT mice compared with those in normal chow-fed WT mice (Fig. 7K). Unexpectedly, HMGCS expression was 1.7-fold higher in Crbn KO mice fed normal chow than in WT fed normal chow. The induction of HMGCS in Crbn KO mice fed a normal chow diet did not correlate with the observed phenotypes of the WT and Crbn KO mice. This may be due to compensatory gene induction to maintain hepatic homeostasis. There were no changes in the expression of Dhcr24, which is involved in cholesterol biosynthesis and HSL, which is involved in lipolysis (Fig. 7L and N). The protein expression patterns of ACC1, FAS, SCD1, G6Pase, and Crbn (Fig. 6A, C, and E–H) were consistent with the mRNA expression profiles shown in Fig. 7. Expression of ACC1 was also increased in WT mice fed an HFD compared with those fed a normal chow diet (Fig. 6E). Overall, these results show that the disruption of Crbn affects the expression of many key metabolic genes. The expression of several lipogenic and gluconeogenic proteins, which are upregulated by HFD, was significantly lower in the livers of Crbn KO mice, which may be explained by the constitutive activation of AMPK (9,23,25–27).
Crbn is evolutionarily conserved between plants and animals and is expressed widely in various mammalian tissues. For validation of the in vivo function of Crbn as a novel regulator of AMPK, Crbn KO mice were established. The Crbn KO mice were viable, with no apparent defects in gross morphology or basic behavior.
As suggested by a previous knockdown study of endogenous CRBN in cultured cell lines (4), endogenous AMPK was constitutively hyperactivated in Crbn KO mice under normal conditions in all tissues tested; therefore, Crbn KO mice were fed an HFD before assessment of the effects of Crbn deficiency on several parameters: body weight, fatty liver, glucose homeostasis, insulin resistance, and metabolic parameters. In general, Crbn KO mice fed an HFD showed a significant improvement in their metabolic profiles compared with HFD-fed WT control mice. Also, Crbn KO mice showed no signs of metabolic syndrome, even after 14 weeks on an HFD. Fat accumulation within the epididymal tissue and liver was also markedly reduced in KO mice. Thus, it was hypothesized that hyperactivity of AMPK in Crbn KO mice was the major contributor to the overall improvement in lipid and glucose homeostasis and insulin sensitivity. It was intriguing that Crbn expression was significantly upregulated, whereas that of P-AMPK was correspondingly downregulated in the livers of WT mice on an HFD. This observation agreed with our previous prediction that Crbn might negatively regulate the functional activity of AMPK in vivo (4).
The current study focused on the effects of Crbn KO on the liver and hepatic metabolism because the liver plays a key role in controlling overall energy status, whereas AMPK coordinates changes in the hepatic enzymes involved in carbohydrate and lipid metabolism. Activation of hepatic AMPK inhibits lipogenesis, cholesterol synthesis, and glucose production (7,8,29). The lower expression of lipogenic regulators, including FAS, ACC1, SCD1, PPARγ, and DGAT2, observed in HFD-fed Crbn KO mice suggests that inhibition of hepatic lipogenesis may contribute to lower levels of fat accumulation. The hepatic expression of G6Pase was lower in Crbn KO mice fed an HFD, suggesting lower levels of gluconeogenesis. Consistent with these findings, the glucose and insulin tolerance tests showed restoration of normal levels in Crbn-deficient mice fed an HFD. Infection with adenovirus encoding a dominant-negative AMPK mutant (Ad-DN-AMPK) increased the glucose output of primary Crbn KO hepatocytes in a dose-dependent manner in comparison with Crbn KO hepatocytes infected with Ad-GFP (Supplementary Fig. 5). Collectively, this suggests that the primary mechanism by which KO of Crbn reduces lipogenesis and gluconeogenesis in the liver operates, at least in part, by regulating AMPK and ACC activity via protein phosphorylation. Furthermore, the levels of Crbn protein and P-AMPK showed a strongly correlation in vivo because the levels of Crbn expression increased as P-AMPK expression decreased in WT mice fed an HFD.
There were several noticeable changes in the expression of key metabolic genes in Crbn KO mice fed a regular chow diet, suggesting a physiological role for Crbn under normal conditions. For example, the expression of lipogenic genes, such as FAS, PPARγ, and DGAT2 and a gluconeogenic gene, G6Pase, was significantly lower. In a good agreement with these findings, hepatic TG levels and the epididymal fat mass were lower in Crbn KO mice fed a regular diet than in WT fed a regular diet. However, morphological phenotypes, including body weight, liver weight, liver morphology, liver section, glucose tolerance, and insulin sensitivity, were similar in WT and Crbn KO mice before the HFD was started. Therefore, Crbn deficiency conferred greater resistance to a metabolic syndrome phenotype under severe pathophysiological conditions (such as a HFD) but not under normal physiological conditions.
In our previous report, AMPK-α1 was identified as a CRBN-binding protein (4). Two isoforms of the AMPK-α, AMPK-α1 and AMPK-α2, are found in mammals (30). AMPK complexes containing each α-subunit isoform were equally represented in terms of total AMPK activity in the liver (26). The current study examined the interaction between AMPK-α2 and Crbn. There was no difference in the binding affinity of Crbn for AMPK-α1 or AMPK-α2 (Supplementary Fig. 6). This was because the putative Crbn-binding site in AMPK-α1 is within a region covering amino acids 394–422 (4), which is also highly conserved in AMPK-α2 (within a region covering amino acids 388–417). These results suggested that Crbn can modulate cellular AMPK, irrespective of its subtype.
It is important to determine whether the Crbn-dependent inhibition of AMPK is also conserved in other organisms, especially humans. Our previous study showed that the activity of AMPK was inhibited by the expression of exogenous Crbn in human, rat, and mouse cell lines (4), so it is likely that the negative regulation of AMPK by CRBN also occurs in humans. Recently, CRBN, which is located in the 3p26–25 region in humans, was identified as a target gene for obesity and insulin. Several single nucleotide polymorphisms close to the CRBN gene are associated with central obesity and high blood pressure in humans and the mice (31), indicating the potential clinical relevance of CRBN in metabolic syndromes.
However, several important questions still need to be addressed. First, the regulation of Crbn gene expression is not understood. Crbn expression was upregulated in the long term by high fat intake (Fig. 6O and 7C). This observation implies that Crbn is induced by an HFD and that CRBN regulates AMPK activity via a negative-feedback loop in vivo. Interestingly, at least three putative sterol regulatory elements and one putative PPARγ binding site are located within −850 bp upstream of the promoter region within the mouse Crbn gene. These two transcriptional factors regulate lipogenesis, which may provide mechanistic insights into the nutrient-dependent modulation of Crbn expression. Second, it is not clear how AMPK is regulated by Crbn in other organs. The physiological roles of AMPK are established in other organs such as adipose tissue and SKM, but it was not possible to discern the contributions of these organs to the metabolic phenotype in Crbn KO mice. The activation of AMPK in WAT and SKM was higher in Crbn KO mice than in WT mice (Supplementary Fig. 7). Thus, it is feasible that other organs relative to metabolism may be affected in a way similar to the liver in Crbn KO mice.
The liver is regarded as the core center for maintaining glucose homeostasis and lipid metabolism, so understanding the normal physiology and the pathophysiology of hepatic metabolism is a prerequisite to understanding whole-body metabolism (7,9,26). Of a variety of tissues tested, the activity of AMPK is lowest in brain and SKM and highest in the liver (32). This may underlie why deletion of Crbn, a negative regulator of AMPK, most affects the liver in Crbn KO mice. In addition, alterations in liver function clearly affect whole-body metabolism and underlie the development of metabolic diseases, including type 2 diabetes and metabolic syndromes (7,9). Thus, the current study of the role of Crbn in hepatic metabolism may be the first step toward a greater understanding of the physiological function of Crbn at the molecular level during normal and diseased states.
In summary, this study provides the first in vivo evidence that Crbn negatively regulates the activation of AMPK and that Crbn deficiency protects mice from obesity, fatty liver, and insulin resistance caused by an HFD. Thus, CRBN may be considered a novel regulator of body metabolism and energy homeostasis.
fn1This article contains Supplementary Data online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-1030/-/DC1.
This work was supported by grants to the Cell Dynamics Research Center (2012-0000760) and the National Leading Research Laboratories (2011-0028665) from the National Research Foundation, funded by the Ministry of Education, Science, and Technology of Korea.
No potential conflicts of interest relevant to this article were reported.
K.M.L. wrote the manuscript, designed and planned the study, and researched data. S.-J.Y. researched data. Y.D.K. contributed to the design of the study and reviewed and edited the manuscript. Y.D.C. researched data and reviewed and edited the manuscript. J.H.N., C.S.C., and H.-S.C. reviewed and edited the manuscript. C.-S.P. wrote the manuscript, designed and planned the study, and reviewed and edited the manuscript. C.-S.P. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
|1.||Higgins JJ,Pucilowska J,Lombardi RQ,Rooney JP. A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation. NeurologyYear: 2004;63:1927–193115557513|
|2.||Jo S,Lee KH,Song S,Jung YK,Park CS. Identification and functional characterization of cereblon as a binding protein for large-conductance calcium-activated potassium channel in rat brain. J NeurochemYear: 2005;94:1212–122416045448|
|3.||Ito T,Ando H,Suzuki T,et al. Identification of a primary target of thalidomide teratogenicity. ScienceYear: 2010;327:1345–135020223979|
|4.||Lee KM,Jo S,Kim H,Lee J,Park CS. Functional modulation of AMP-activated protein kinase by cereblon. Biochim Biophys ActaYear: 2011;1813:448–45521232561|
|5.||Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell BiolYear: 2007;8:774–78517712357|
|6.||Hawley SA,Davison M,Woods A,et al. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J Biol ChemYear: 1996;271:27879–278878910387|
|7.||Viollet B,Guigas B,Leclerc J,et al. AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol (Oxf)Year: 2009;196:81–9819245656|
|8.||Shackelford DB,Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev CancerYear: 2009;9:563–57519629071|
|9.||Viollet B,Foretz M,Guigas B,et al. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J PhysiolYear: 2006;574:41–5316644802|
|10.||Bergeron R,Previs SF,Cline GW,et al. Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. DiabetesYear: 2001;50:1076–108211334411|
|11.||Hardie DG. AMP-activated protein kinase as a drug target. Annu Rev Pharmacol ToxicolYear: 2007;47:185–21016879084|
|12.||Cool B,Zinker B,Chiou W,et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell MetabYear: 2006;3:403–41616753576|
|13.||Dasgupta B,Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci USAYear: 2007;104:7217–722217438283|
|14.||Ramamurthy S,Ronnett GV. Developing a head for energy sensing: AMP-activated protein kinase as a multifunctional metabolic sensor in the brain. J PhysiolYear: 2006;574:85–9316690704|
|15.||Kelley DE,McKolanis TM,Hegazi RA,Kuller LH,Kalhan SC. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol MetabYear: 2003;285:E906–E91612959938|
|16.||Kim EJ,Yoon YS,Hong S,et al. Retinoic acid receptor-related orphan receptor α-induced activation of adenosine monophosphate-activated protein kinase results in attenuation of hepatic steatosis. HepatologyYear: 2012;55:1379–138822183856|
|17.||Serino M,Menghini R,Fiorentino L,et al. Mice heterozygous for tumor necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes. DiabetesYear: 2007;56:2541–254617646208|
|18.||Shimano H. Sterol regulatory element-binding protein-1 as a dominant transcription factor for gene regulation of lipogenic enzymes in the liver. Trends Cardiovasc MedYear: 2000;10:275–27811343966|
|19.||Horton JD,Goldstein JL,Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin InvestYear: 2002;109:1125–113111994399|
|20.||Bocher V,Pineda-Torra I,Fruchart JC,Staels B. PPARs: transcription factors controlling lipid and lipoprotein metabolism. Ann N Y Acad SciYear: 2002;967:7–1812079830|
|21.||Lehrke M,Lazar MA. The many faces of PPARgamma. CellYear: 2005;123:993–99916360030|
|22.||Cases S,Smith SJ,Zheng YW,et al. Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proc Natl Acad Sci USAYear: 1998;95:13018–130239789033|
|23.||Niu Y,Li S,Na L,et al. Mangiferin decreases plasma free fatty acids through promoting its catabolism in liver by activation of AMPK. PLoS ONEYear: 2012;7:e3078222292039|
|24.||Vaulont S,Munnich A,Decaux JF,Kahn A. Transcriptional and post-transcriptional regulation of L-type pyruvate kinase gene expression in rat liver. J Biol ChemYear: 1986;261:7621–76253011791|
|25.||da Silva Xavier G,Leclerc I,Salt IP,et al. Role of AMP-activated protein kinase in the regulation by glucose of islet beta cell gene expression. Proc Natl Acad Sci USAYear: 2000;97:4023–402810760274|
|26.||Viollet B,Athea Y,Mounier R,et al. AMPK: Lessons from transgenic and knockout animals. Front BiosciYear: 2009;14:19–4419273052|
|27.||Foretz M,Ancellin N,Andreelli F,et al. Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. DiabetesYear: 2005;54:1331–133915855317|
|28.||Fisher FM,Chui PC,Antonellis PJ,et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. DiabetesYear: 2010;59:2781–278920682689|
|29.||Fryer LG,Carling D. AMP-activated protein kinase and the metabolic syndrome. Biochem Soc TransYear: 2005;33:362–36615787607|
|30.||Stapleton D,Mitchelhill KI,Gao G,et al. Mammalian AMP-activated protein kinase subfamily. J Biol ChemYear: 1996;271:611–6148557660|
|31.||Kraja AT,Lawson HA,Arnett DK,et al. Obesity-insulin targeted genes in the 3p26-25 region in human studies and LG/J and SM/J mice. MetabolismYear: 2012;61:1129–114122386932|
|32.||Davies SP,Carling D,Hardie DG. Tissue distribution of the AMP-activated protein kinase, and lack of activation by cyclic-AMP-dependent protein kinase, studied using a specific and sensitive peptide assay. Eur J BiochemYear: 1989;186:123–1282574667|
Previous Document: Nox2 NADPH oxidase has a critical role in insulin resistance-related endothelial cell dysfunction.
Next Document: Reduced adipose tissue macrophage content is associated with improved insulin sensitivity in thiazol...